



Correction to: Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor

Alice Tsai · Shu-Pei Wu · Eric Haseltine · Sanjeev Kumar ·

Samuel M. Moskowitz · Paul Panorchan · Kushal Shah

To view enhanced content go to www.pulmonarytherapy-open.com

Published online: August 27, 2020

© The Author(s) 2020

Correction to: Pulm Ther <https://doi.org/10.1007/s41030-020-00124-7>

The original version of this article unfortunately contained a mistake. In section “Methods”, the word “physiochemical” was incorrectly changed to “physicochemical” in four instances. The correct sentences are as follows:

First sentence of subsection “Ivacaftor PBPK Model”: The physiochemical properties of ivacaftor [e.g., permeability, blood-to-plasma ratio, plasma protein binding, logarithm of acid dissociation constant (pKa)] were obtained from internal sources. All ivacaftor PBPK model parameters are available in Supplementary Table S1.

First sentence of subsection “Lumacaftor PBPK Model”: The physiochemical properties of lumacaftor (e.g., permeability, blood-to-plasma ratio, plasma protein binding, pKa) were obtained from internal sources.

First sentence of subsection “Tezacaftor PBPK Model”: The physiochemical properties of tezacaftor (e.g., permeability, blood-to-plasma ratio,

plasma protein binding, pKa) were obtained from internal sources.

First sentence of subsection “Elexacaftor PBPK Model”: The physiochemical and ADME properties of elexacaftor (e.g., permeability, blood-to-plasma ratio, plasma protein binding), as well as relevant clinical data, were obtained from internal sources.

The original article has been corrected.

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s41030-020-00124-7>.

A. Tsai (✉) · S.-P. Wu · E. Haseltine · S. Kumar ·
S. M. Moskowitz · P. Panorchan · K. Shah
Vertex Pharmaceuticals Incorporated, Boston, MA,
USA
e-mail: alice_tsai@vrtx.com